Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective Study of Hema-Plus (recombinant human erythropoietin alfa) in chronic kidney disease patients at Siriraj Hospital
TCTR20170808001Phase 4Active, not recruiting
- Sponsor
- Apexcela
- Start
- Aug 2017
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in chronic kidney disease (CKD) and anaemia, sponsored by Apexcela. Primary endpoints: Efficacy of Hema-Plus and Safety of Hema-Plus. Started Aug 2017; status: active, not recruiting.
02
Conditions
chronic kidney disease (CKD)anaemia
Beyond the preview
Go deeper on TCTR20170808001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20170808001.